# Nektar Therapeutics (NKTR) — Earnings

NKTR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nktr/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$1.23 |
| EPS estimate | −$1.97 |
| EPS surprise | +37.60% |
| Revenue surprise | −2.82% |
| Revenue | $10.1M |
| Revenue estimate | $10.4M |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/0b83fc0d-9c8b-c268-e547-86ca8bcf4876.html) |

Nektar Therapeutics reported Q2 2026 results on August 13, 2026. The company posted a loss of $1.23 per share, narrower than the $1.97 loss analysts expected, a 37.60% beat. Revenue was $10.1 million, slightly below the $10.4 million estimate. In Q2 2025 the loss was $2.95 per share and revenue was $11.2 million, so revenue fell 9.8% year over year.

Nektar posted a loss in 19 of the 20 quarters in the table. The only profit was $0.45 per share in Q4 2024. Annual losses per share were $29.55 in 2022, $21.90 in 2023, $8.85 in 2024 and $10.20 in 2025. Revenue fell from $98.4 million in 2024 to $55.3 million in 2025, and quarterly revenue has stayed between $10 million and $12 million in four of the last five quarters. The first half of 2026 lost $3.05 per share, against $6.55 a year earlier. The loss came in narrower than expected in 13 of the 20 quarters, including Q2 2026.

Q3 results came out between November 3 and November 7 in each of the past five years. That points to early November 2026 for the next report, which will show whether the smaller first-half losses continue.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | −$1.97 | −$1.23 | 37.60% | $10.4M | $10.1M |
| Q1 2026 | May 7, 2026 | −$1.58 | −$1.82 | -15.02% | $10.7M | $10.9M |
| Q4 2025 | Mar 12, 2026 | −$2.47 | −$1.78 | 28.05% | $10.2M | $21.8M |
| Q3 2025 | Nov 6, 2025 | −$2.68 | −$1.87 | 30.35% | $10.1M | $11.8M |
| Q2 2025 | Aug 7, 2025 | −$3.03 | −$2.95 | 2.56% | $9.5M | $11.2M |
| Q1 2025 | May 8, 2025 | −$2.56 | −$3.60 | -40.39% | $15.4M | $10.5M |
| Q4 2024 | Mar 12, 2025 | −$2.03 | $0.45 | 122.12% | $35.5M | $29.2M |
| Q3 2024 | Nov 7, 2024 | −$2.99 | −$2.70 | 9.55% | $19.2M | $24.1M |
| Q2 2024 | Aug 8, 2024 | −$2.78 | −$3.75 | -35.14% | $18.2M | $23.5M |
| Q1 2024 | May 9, 2024 | −$2.85 | −$2.85 | 0.00% | $15.3M | $21.6M |
| Q4 2023 | Mar 4, 2024 | −$3.16 | −$3.30 | -4.54% | $21.4M | $23.9M |
| Q3 2023 | Nov 7, 2023 | −$2.97 | −$3.60 | -21.02% | $21.3M | $24.1M |
| Q2 2023 | Aug 8, 2023 | −$4.22 | −$4.05 | 4.08% | $21.8M | $20.5M |
| Q1 2023 | May 9, 2023 | −$3.72 | −$10.95 | -194.31% | $19.4M | $21.6M |
| Q4 2022 | Feb 28, 2023 | −$6.78 | −$4.80 | 29.19% | $22.1M | $22.0M |
| Q3 2022 | Nov 3, 2022 | −$6.74 | −$4.65 | 30.96% | $22.6M | $23.6M |
| Q2 2022 | Aug 4, 2022 | −$14.55 | −$12.75 | 12.37% | $22.6M | $21.6M |
| Q1 2022 | May 5, 2022 | −$9.46 | −$7.35 | 22.33% | $24.3M | $24.8M |
| Q4 2021 | Feb 28, 2022 | −$12.05 | −$11.85 | 1.66% | $34.3M | $25.0M |
| Q3 2021 | Nov 4, 2021 | −$11.97 | −$10.50 | 12.28% | $28.1M | $24.9M |

## Frequently Asked Questions

### When did Nektar Therapeutics (NKTR) last report earnings?

Nektar Therapeutics last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did NKTR beat earnings estimates?

Yes. Nektar Therapeutics reported EPS of −$1.23 for Q2 2026 against a −$1.97 estimate — a 37.60% beat.

### How much revenue did NKTR report last quarter?

Nektar Therapeutics reported $10.1M in revenue for Q2 2026, against a consensus estimate of $10.4M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).